Ipamorelin vs. GHRP-6: Comparing Growth Hormone Secretagogues in Research
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
Ipamorelin and GHRP-6 are both synthetic agonists of the growth hormone secretagogue receptor (GHSR), but they differ significantly in their selectivity profiles and the hormonal responses they produce in research models. This difference in selectivity has made Ipamorelin a preferred research tool for studies requiring isolated GH stimulation.
GHRP-6: Broad Secretagogue Activity
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a hexapeptide that was among the first synthetic GHSR agonists characterized. It stimulates GH release potently but also produces significant increases in cortisol, ACTH, and prolactin in animal models and humans.
The cortisol and ACTH responses to GHRP-6 are well-documented. Arvat et al. (1997) demonstrated that GHRP-6 administration in healthy adults produced significant ACTH and cortisol increases alongside GH secretion [1]. This broad hormonal activation complicates the interpretation of research results when the goal is to study GH-specific effects.
GHRP-6 also stimulates appetite through ghrelin receptor activation, which has been studied as a potential research application in models of cachexia and appetite regulation.
Ipamorelin: Selective GH Release
Ipamorelin was specifically developed to address the selectivity limitations of earlier GHRPs. Raun et al. (1998) characterized Ipamorelin as the first GHSR agonist to produce selective GH release without significant effects on cortisol, prolactin, or ACTH at doses producing maximal GH stimulation [2].
This selectivity profile makes Ipamorelin a more precise research tool for studies examining GH-specific effects on body composition, bone density, or metabolism without the confounding effects of cortisol elevation.
Comparative Selectivity
| Hormone Response | GHRP-6 | Ipamorelin | |---|---|---| | GH release | Strong | Strong | | Cortisol increase | Significant | Minimal | | ACTH increase | Significant | Minimal | | Prolactin increase | Moderate | Minimal | | Appetite stimulation | Yes (ghrelin-mediated) | Minimal |
Research Applications
GHRP-6 is appropriate for research models examining the full spectrum of GHSR activation, including appetite regulation, or studies where cortisol response is part of the research question.
Ipamorelin is preferred for research models requiring selective GH stimulation without confounding hormonal effects — for example, studies of GH effects on bone mineral density, lean mass, or fat metabolism where cortisol elevation would confound results.
Conclusion
Ipamorelin's superior selectivity profile makes it the preferred GHSR agonist for most research applications requiring isolated GH stimulation. GHRP-6 remains useful for research models where its broader hormonal activity is relevant to the research question.
For research use only. Not for human or animal consumption.
References
- Arvat, E., et al. (1997). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 82(9), 2991–2999.
- Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
All compounds referenced in this article are available as research-grade peptides, independently verified by third-party laboratories.